Joost W. J. van Esser

Prevention of Epstein-Barr virus–lymphoproliferative disease by molecular monitoring and preemptive rituximab in high-risk patients after allogeneic stem cell transplantation

Joost W. J. van Esser, Hubert G.M. Niesters, Bronno van der Holt et al. · Blood · 2002 · 401 citations · Full text

Life Sciences, Immunology, Pharmacotherapy +17

Epstein-Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell–depleted SCT

Joost W. J. van Esser, Bronno van der Holt, Ellen Meijer et al. · Blood · 2001 · 371 citations · Full text

Medicine, Hematology, Immunology +14

Increased transplant-related morbidity and mortality in CMV-seropositive patients despite highly effective prevention of CMV disease after allogeneic T-cell–depleted stem cell transplantation

Annoek E. C. Broers, Bronno van der Holt, Joost W. J. van Esser et al. · Blood · 2000 · 338 citations · Full text

Medicine, Immunology, Infectious Diseases +17

Tetramer-based quantification of cytomegalovirus (CMV)–specific CD8+ T lymphocytes in T-cell–depleted stem cell grafts and after transplantation may identify patients at risk for progressive CMV infection

Jan W. Gratama, Joost W. J. van Esser, C. B. H. W. Lamers et al. · Blood · 2001 · 278 citations · Full text

Life Sciences, Hematology, Immunology +14

Impaired recovery of Epstein-Barr virus (EBV)—specific CD8+ T lymphocytes after partially T-depleted allogeneic stem cell transplantation may identify patients at very high risk for progressive EBV reactivation and lymphoproliferative disease

Pauline Meij, Joost W. J. van Esser, Hubert G.M. Niesters et al. · Blood · 2003 · 139 citations · Full text

Medicine, Hematology, Immunology +15